Lyra Therapeutics Inc
$ 1.46
0.34%
24 Feb - close price
- Market Cap 2,573,600 USD
- Current Price $ 1.46
- High / Low $ 1.47 / 1.39
- Stock P/E N/A
- Book Value -2.63
- EPS -22.90
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -4.04 %
- 52 Week High 34.00
- 52 Week Low 1.21
About
Lyra Therapeutics, Inc., a clinical-stage therapeutic company, focuses on the development and commercialization of new integrated drug and delivery solutions for the localized treatment of patients with diseases of the ear, nose and throat. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$16.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-04-28 | 2025-03-19 | 2024-11-05 | 2024-08-14 | 2024-04-30 | 2024-03-21 | 2023-11-07 | 2023-08-08 | 2023-05-12 | 2023-03-29 |
| Reported EPS | -3.38 | -5.2194 | -0.13 | -0.1419 | -0.1385 | -0.74 | -0.35 | -0.22 | -0.27 | -0.32 | -0.44 | -0.38 |
| Estimated EPS | -0.185 | -0.165 | -0.1367 | -0.13 | -0.205 | -0.33 | -0.26 | -0.31 | -0.32 | -0.42 | -0.36 | -0.41 |
| Surprise | -3.195 | -5.0544 | 0.0067 | -0.0119 | 0.0665 | -0.41 | -0.09 | 0.09 | 0.05 | 0.1 | -0.08 | 0.03 |
| Surprise Percentage | -1727.027% | -3063.2727% | 4.9012% | -9.1538% | 32.439% | -124.2424% | -34.6154% | 29.0323% | 15.625% | 23.8095% | -22.2222% | 7.3171% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LYRA
.jpg)
2026-02-11 08:27:14
Lyra Therapeutics is at risk of being delisted from Nasdaq after its primary clinical development program was halted, leading to its classification as a non-operating public shell. The company is appealing the delisting decision and conducting a strategic review to leverage its remaining assets and clinical data, aiming to extend its financial runway through mid-2026 with minimal operations. Investors are awaiting the upcoming financial report for updates on the company's future as a publicly listed entity.
2026-02-07 13:05:33
Nasdaq is moving to delist Lyra Therapeutics (LYRA) due to its classification as a "public shell" lacking an operating business and its failure to meet the minimum stockholders' equity requirement. This decision follows Lyra's suspension of its lead product development and termination of most employees. Lyra has requested a hearing to appeal the delisting, which temporarily stays the process, but there is no guarantee of continued listing.
2026-02-06 21:29:35
Lyra Therapeutics is facing delisting from Nasdaq after the exchange determined it to be a public shell company due to suspending its lead drug candidate's development and laying off most staff. The company also failed to meet the minimum $2.5 million stockholders' equity requirement. Lyra has appealed the decision, but its future as a publicly traded entity remains uncertain, highlighting significant risks for shareholders.
2026-02-06 21:29:35
Lyra Therapeutics received a delisting notice from Nasdaq on February 2, 2026, due to concerns about being a public shell company and non-compliance with the $2.5 million stockholders' equity requirement. The company has requested a hearing, which temporarily prevents suspension and delisting, but there is no guarantee its request for continued listing will be granted. This information is based on an SEC filing from February 6, 2026.
2026-01-13 12:56:47
Lyra Therapeutics has announced the suspension of further development for LYR-210, its lead product candidate for chronic rhinosinusitis. This decision was made by the Board of Directors in connection with a review of strategic options, leading to a workforce reduction impacting its 28 remaining employees and other cost-saving measures. The company is retaining key executives as consultants to explore strategic alternatives for LYR-210.
2026-01-13 08:56:47
Lyra Therapeutics (NASDAQ:LYRA) has announced it is halting the development of its lead product candidate, LYR-210, for chronic rhinosinusitis (CRS) and will implement a workforce reduction affecting all 28 remaining employees. This decision comes despite positive Phase 3 trial data, with the company opting not to pursue an additional required Phase 3 trial and instead exploring strategic alternatives for the business. The company's stock has seen a significant decline over the past year, though it recently experienced a short-term gain.
